Equities

Shineco Inc

SISI:NAQ

Shineco Inc

Actions
Consumer Staples Food Producers
  • Price (USD)2.78
  • Today's Change0.50 / 21.93%
  • Shares traded282.28k
  • 1 Year change-46.54%
  • Beta-0.0498
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shineco Inc is a holding company. The Company provides health and well-being focused plant-based products by using its subsidiaries' and variable interest entities' vertically and horizontally integrated production, distribution and sales channels. The Company operates through three segments. Developing, producing and distributing innovative rapid diagnostic products and related medical devices for the most common diseases (Rapid Diagnostic and Other Products) :This segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases; Producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as fresh fruit s (Other agricultural products): This segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as tra

  • Revenue in USD (TTM)5.62m
  • Net income in USD-14.34m
  • Incorporated1997
  • Employees87.00
  • Location
    Shineco IncT1, South Tower, Jiazhaoye SquareBEIJING 100022ChinaCHN
  • Phone+86 1 068329620
  • Fax+1 3 022669940
  • Websitehttps://www.biosisi.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imunon Inc0.00-18.85m12.50m33.00--1.47-----2.02-2.020.000.90410.00----0.00-66.82-50.18-91.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
ELEVAI Labs Inc2.18m-4.62m12.56m18.00--4.63--5.75-0.2665-0.26650.1260.1435------121,351.70--------67.84---211.42--1.80--0.00--123.50---138.94------
Kiora Pharmaceuticals Inc16.00m2.28m12.66m12.00--0.36265.450.791-1.60-1.601.211.330.5427--8.641,333,333.009.52-70.5210.17-81.86----17.55-2,040.61----0.00------3.97------
Dominari Holdings Inc3.41m-24.56m12.76m26.00--0.2677--3.75-4.64-4.640.63058.030.0539--0.8023131,000.00-38.88-26.82-39.93-27.45-----721.11-3,353.52----0.00----135.7512.72--63.99--
Nexgel Inc4.74m-3.20m13.02m19.00--2.72--2.75-0.5535-0.55350.82080.76880.44283.248.46249,263.20-30.72-44.61-39.92-56.1920.145.02-69.38-180.981.41--0.1819--99.6613.0633.48------
CV Sciences Inc15.86m-3.23m13.06m42.00--5.53--0.8235-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Cell MedX Corp70.00-96.91k13.08m0.00------186,834.30-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Inhibikase Therapeutics Inc195.98k-19.20m13.10m8.00--1.73--66.84-3.38-3.380.0341.050.01--6.0824,497.50-97.88-66.49-118.76-85.55-----9,797.30-1,139.14----0.00--111.03-42.21-5.40------
Senti Biosciences Inc1.28m-86.11m13.18m48.00--0.2347--10.34-1.93-1.440.02851.230.0097--2.9426,562.50-65.33---71.42-------6,753.80------0.0018---40.25---67.94------
Check Cap Ltd0.00-17.57m13.28m85.00--0.5607-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
Shineco Inc5.62m-14.34m13.34m87.00--0.3707--2.37-3.98-2.321.365.580.06640.481.4564,633.68-19.79-12.77-38.28-16.8412.7725.88-298.09-102.060.4842-8.140.3908-----58.35-33.86------
Monopar Therapeutics Inc0.00-7.61m13.44m10.00--1.80-----0.5289-0.52890.000.42770.00----0.00-73.36-54.07-92.67-60.60------------0.00------20.10------
Pieris Pharmaceuticals Inc40.93m-16.25m13.60m46.00--0.5798--0.3322-12.74-12.7434.0517.760.7324--28.25889,717.40-29.09-28.41-52.98-39.69-----39.71-94.61----0.00--65.288.0326.25---36.82--
CERo Therapeutics Holdings Inc0.00-2.54m13.63m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Mannatech Inc127.23m-1.66m14.14m213.00--1.35--0.1111-0.899-0.89968.075.542.771.93561.74597,342.80-3.624.39-9.679.1678.0177.87-1.311.720.5584--0.138488.33-3.83-5.3350.13---20.38--
Data as of Jun 07 2024. Currency figures normalised to Shineco Inc's reporting currency: US Dollar USD

Institutional shareholders

8.72%Per cent of shares held by top holders
HolderShares% Held
G1 Execution Services LLCas of 31 Mar 202441.83k6.52%
UBS Securities LLCas of 31 Mar 202413.75k2.15%
Qube Research & Technologies Ltd.as of 31 Mar 2024300.000.05%
XTX Markets LLCas of 31 Mar 20240.000.00%
Two Sigma Securities LLCas of 31 Mar 20240.000.00%
Renaissance Technologies LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.